Stock ETX E-THERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials e-therapeutics plc

Equities

ETX

GB00B2823H99

Biotechnology & Medical Research

Market Closed - London S.E.
Other stock markets
 11:35:26 2024-04-30 am EDT 		5-day change 1st Jan Change
9.875 GBX +7.63% Intraday chart for e-therapeutics plc +11.58% +19.84%
Apr. 10 FTSE 100 Closes Up 0.3% as U.S. Uncertainty Boosts Appetite for U.K. Stocks DJ
Apr. 10 E-Therapeutics says company faces lack of interest as UK listing AN

Valuation

Fiscal Period: January 2018 2019 2020 2021 2022 2023
Capitalization 1 25.85 14.11 10.09 78.37 172.4 93.73
Enterprise Value (EV) 1 16.25 8.202 6.32 65.37 146.4 62.33
P/E ratio -4.82 x -3.53 x -4.3 x -18.9 x -20.3 x -10.5 x
Yield - - - - - -
Capitalization / Revenue - 320,595,864 x 22,132,031 x 247,221,047 x 361,386,390 x 197,321,373 x
EV / Revenue - 186,414,045 x 13,860,101 x 206,198,965 x 306,956,621 x 131,228,741 x
EV / EBITDA -2.47 x -1.62 x -2.23 x -16.1 x -15.4 x -6.13 x
EV / FCF -5.08 x -2.81 x -4.27 x -28.5 x -25 x -10.6 x
FCF Yield -19.7% -35.6% -23.4% -3.5% -4% -9.47%
Price to Book 2.41 x 2.07 x 2.24 x 5.64 x 6.16 x 2.84 x
Nbr of stocks (in thousands) 268,531 268,690 269,125 420,774 514,571 582,159
Reference price 2 0.0962 0.0525 0.0375 0.1862 0.3350 0.1610
Announcement Date 4/4/18 3/6/19 3/31/20 5/21/21 5/4/22 5/4/23
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: January 2018 2019 2020 2021 2022 2023
Net sales - 0.044 0.456 0.317 0.477 0.475
EBITDA 1 -6.586 -5.06 -2.84 -4.049 -9.525 -10.17
EBIT 1 -6.648 -5.114 -2.888 -4.085 -9.57 -10.24
Operating Margin - -11,622.73% -633.33% -1,288.64% -2,006.29% -2,155.58%
Earnings before Tax (EBT) 1 -6.719 -5.085 -2.873 -4.468 -9.519 -9.772
Net income 1 -5.359 -3.999 -2.347 -3.684 -8.07 -8.274
Net margin - -9,088.64% -514.69% -1,162.15% -1,691.82% -1,741.89%
EPS 2 -0.0200 -0.0149 -0.008729 -0.009870 -0.0165 -0.0154
Free Cash Flow 1 -3.196 -2.92 -1.481 -2.29 -5.85 -5.904
FCF margin - -6,636.93% -324.78% -722.44% -1,226.52% -1,242.89%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/4/18 3/6/19 3/31/20 5/21/21 5/4/22 5/4/23
1GBP in Million2GBP
Estimates

Balance Sheet Analysis

Fiscal Period: January 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 9.6 5.9 3.77 13 26 31.4
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -3.2 -2.92 -1.48 -2.29 -5.85 -5.9
ROE (net income / shareholders' equity) -40.1% -45.6% -41.5% -40.1% -38.6% -27.2%
ROA (Net income/ Total Assets) -28% -33.2% -29.4% -26.7% -27.1% -19.9%
Assets 1 19.15 12.06 7.993 13.78 29.73 41.47
Book Value Per Share 2 0.0400 0.0300 0.0200 0.0300 0.0500 0.0600
Cash Flow per Share 2 0.0300 0.0200 0.0100 0.0300 0.0200 0.0500
Capex 1 0.07 0.01 0.01 0.05 0.11 0.07
Capex / Sales - 18.18% 1.1% 16.72% 22.22% 14.32%
Announcement Date 4/4/18 3/6/19 3/31/20 5/21/21 5/4/22 5/4/23
1GBP in Million2GBP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
E-THERAPEUTICS PLC Stock e-therapeutics plc
+19.84% 67.29M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.41% 42.86B
MODERNA, INC. Stock Moderna, Inc.
+11.75% 42.74B
LONZA GROUP AG Stock Lonza Group AG
+44.30% 41.36B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 27.68B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+5.53% 25.15B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.23% 18.63B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.56% 12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.04% 11.92B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.06% 11.21B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ETX Stock
  4. Financials e-therapeutics plc